Pancreatic Cancer Research

ResearcherUniversity of GeorgiaActive in the last 2 years

Yangzom Doma Bhutia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6927-075X; OpenAlex author ID A5050131267, A5103021647; NIH RePORTER profile ID 10194203. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 6)
Trials
0
Grants
2
Labs led
1
Collaborators
16
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers, 1 grant · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper, 1 grant

Papers 11

  1. Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcinoma. Last author DOI 10.1042/bcj20250155↗
  2. Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer. Last author DOI 10.1038/s41598-023-43983-1↗
  3. Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth. Last author DOI 10.1042/bcj20210851↗
  4. Deletion of Slc6a14 reduces cancer growth and metastatic spread and improves survival in KPC mouse model of spontaneous pancreatic cancer. Last author DOI 10.1042/bcj20210855↗
  5. PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target. Last author DOI 10.1042/bcj20210377↗
  6. Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer. Co-author DOI 10.1016/j.ajps.2020.02.003↗
  7. Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells. Co-author DOI 10.1042/bcj20200275↗
  8. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Last author DOI 10.1111/bph.13616↗
  9. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. Co-author DOI 10.1371/journal.pone.0053436↗
  10. Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle deliver… Co-author DOI 10.1371/journal.pone.0071196↗
  11. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-10-2736↗

Grants 2

  1. SLC6A14 as a unique drug target to treat pancreatic cancer R01CA262420↗
  2. Carbidopa as an inhibitor of the TrpT/ID01 functional complex: A novel immunotherapy agent R03CA223271↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vadivel Ganapathy · 7 shared papers, 2016–2026 · strength 1.02
  2. Ksenija Korać · 4 shared papers, 2021–2023 · strength 0.66
  3. Tyler Sniegowski · 4 shared papers, 2021–2023 · strength 0.66
  4. Bradley K. Schniers · 4 shared papers, 2020–2022 · strength 0.59
  5. Mosharaf Mahmud Syed · 2 shared papers, 2023–2026 · strength 0.45
  6. Ruijie Chen · 2 shared papers, 2020–2026 · strength 0.40
  7. Longfa Kou · 2 shared papers, 2020–2026 · strength 0.40
  8. Aimin Cai · 1 shared paper, 2020 · strength 0.11
  9. Hailun Zheng · 1 shared paper, 2020 · strength 0.11
  10. Sau Wai Hung · 3 shared papers, 2011–2013 · strength 0.11
  11. Rajgopal Govindarajan · 3 shared papers, 2011–2013 · strength 0.11
  12. Carolina Torres · 1 shared paper, 2020 · strength 0.09
  13. Paul J. Grippo · 1 shared paper, 2020 · strength 0.09
  14. Veena Coothankandaswamy · 1 shared paper, 2016 · strength 0.06
  15. Pankaj Kumar Singh · 1 shared paper, 2016 · strength 0.06
  16. Hardik R. Mody · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.